Robert W. Baird Has Lowered Expectations for Fortrea (NASDAQ:FTRE) Stock Price

Fortrea (NASDAQ:FTRE) had its target price lowered by analysts at Robert W. Baird from $19.00 to $16.00 in a note issued to investors on Friday,Benzinga reports. The firm presently has an “outperform” rating on the stock. Robert W. Baird’s price objective would suggest a potential upside of 49.25% from the company’s current price.

Other analysts have also recently issued reports about the stock. Mizuho set a $15.00 price target on shares of Fortrea in a research report on Friday, January 9th. Wedbush set a $21.00 price objective on Fortrea in a research note on Thursday, December 11th. Citigroup raised Fortrea from a “neutral” rating to a “buy” rating and upped their target price for the stock from $12.00 to $21.00 in a research report on Thursday, December 11th. Evercore set a $25.00 target price on Fortrea and gave the company an “outperform” rating in a research note on Tuesday, January 6th. Finally, Truist Financial set a $22.00 target price on Fortrea and gave the company a “buy” rating in a report on Thursday, January 8th. Four investment analysts have rated the stock with a Buy rating, seven have issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, Fortrea currently has an average rating of “Hold” and an average price target of $16.15.

Fortrea Stock Down 0.7%

FTRE opened at $10.72 on Friday. Fortrea has a 1 year low of $3.97 and a 1 year high of $18.67. The firm has a 50 day moving average price of $15.14 and a 200 day moving average price of $12.34. The company has a debt-to-equity ratio of 1.81, a quick ratio of 1.00 and a current ratio of 1.00. The company has a market cap of $990.53 million, a PE ratio of -0.98, a price-to-earnings-growth ratio of 0.33 and a beta of 1.59.

Fortrea (NASDAQ:FTRE) last announced its quarterly earnings results on Thursday, February 26th. The company reported $0.09 earnings per share for the quarter, missing analysts’ consensus estimates of $0.16 by ($0.07). Fortrea had a negative net margin of 36.21% and a positive return on equity of 5.97%. The business had revenue of $660.50 million for the quarter, compared to analyst estimates of $665.22 million. Sell-side analysts expect that Fortrea will post 0.51 earnings per share for the current year.

Hedge Funds Weigh In On Fortrea

Several institutional investors and hedge funds have recently made changes to their positions in the business. Sanctuary Advisors LLC grew its position in shares of Fortrea by 1.7% during the fourth quarter. Sanctuary Advisors LLC now owns 36,648 shares of the company’s stock worth $632,000 after buying an additional 627 shares in the last quarter. Oregon Public Employees Retirement Fund boosted its stake in Fortrea by 3.4% during the 4th quarter. Oregon Public Employees Retirement Fund now owns 21,166 shares of the company’s stock valued at $365,000 after acquiring an additional 700 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. grew its holdings in Fortrea by 27.9% during the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 4,490 shares of the company’s stock worth $77,000 after acquiring an additional 980 shares in the last quarter. Amalgamated Bank increased its position in shares of Fortrea by 4.0% in the 3rd quarter. Amalgamated Bank now owns 26,688 shares of the company’s stock worth $225,000 after purchasing an additional 1,026 shares during the last quarter. Finally, Larson Financial Group LLC increased its position in shares of Fortrea by 136.7% in the 4th quarter. Larson Financial Group LLC now owns 1,856 shares of the company’s stock worth $32,000 after purchasing an additional 1,072 shares during the last quarter.

Key Headlines Impacting Fortrea

Here are the key news stories impacting Fortrea this week:

• Positive Sentiment: Management said full‑year revenue and adjusted EBITDA delivered in line with targets and that full‑year cost savings exceeded prior targets — a reassurance on operational execution. Fortrea Reports Fourth Quarter and Full-Year 2025 Results; Issues Full-Year 2026 Guidance
• Positive Sentiment: Robert W. Baird kept an “outperform” rating and a $16 price target (implying ~49% upside vs. current levels), signaling some analysts remain bullish on the company’s longer‑term outlook. Baird price target note
• Neutral Sentiment: Several full transcripts and earnings‑call highlights were published (useful for parsing management commentary and client/contract trends), giving investors primary‑source detail on drivers and margin dynamics. Fortrea Holdings Inc (FTRE) Q4 2025 Earnings Call Highlights
• Neutral Sentiment: Analyst coverage remains active — a recent Benzinga roundup reviews seven ratings, which can amplify volatility as differing views are disseminated. Deep Dive Into Fortrea Holdings Stock: Analyst Perspectives (7 Ratings)
• Negative Sentiment: Q4 results missed consensus: reported EPS $0.09 vs. $0.16 expected, and revenue $660.5M vs. ~$665M expected — the headline misses are driving the immediate negative reaction. Fortrea Q4 Earnings and Revenues Lag Estimates (Zacks)
• Negative Sentiment: Barclays cut its price target to $12 and set an “equal weight” rating — a formal shift toward neutrality/less bullishness that can pressure sentiment and weaken near‑term buyer conviction. Barclays price target cut
• Negative Sentiment: FY‑2026 revenue guidance was given in a range (~$2.6B–$2.7B), which sits slightly below consensus at the top end — the cautious top‑line outlook and an unclear EPS guide left some investors wanting more upside visibility. Fortrea Reports Fourth Quarter and Full-Year 2025 Results; Issues Full-Year 2026 Guidance

Fortrea Company Profile

Fortrea, Inc is a global contract development and manufacturing organization (CDMO) that provides integrated solutions for pharmaceutical and biotechnology companies. Established as a spin-off from Thermo Fisher Scientific’s Pharma Services business in October 2023, Fortrea leverages a legacy of scientific expertise and manufacturing scale to support drug development from early-stage research through commercial production. The company’s comprehensive offerings address the complex needs of both small-molecule and biologics programs, making it a single source for clients seeking to accelerate timelines and manage costs.

Fortrea’s core services encompass analytical and formulation development, process optimization, clinical and commercial manufacturing, and packaging services.